Galectin-1 (gal-1) is a 14-kDa laminin-binding galectin involved in several biologic events including regulation of cancer cell proliferation and adhesion to the matrix. In this study, we examined gal-1 expression in 30 human epithelial ovary carcinoma samples by Western and Northern blotting and by immunohistochemistry. Gal-1 mRNA levels were increased in more than 95% of the examined ovary carcinoma samples, compared with a wedge resection of a normal ovary.
T he galectins constitute a growing family of soluble lactose-binding lectins sharing affinity for ␤-galactoside residues and significant sequence similarity in their carbohydrate-binding site . A large body of literature has described their possible involvement in numerous biologic events related to carbohydrate recognition during cell-cell and cell-matrix interactions. Galectin-1 (gal-1), a pleiotropic homodimeric protein whose 14-kDa monomer is almost exclusively composed of a carbohydrate recognition domain, is involved in cell-cell and cellmatrix interactions Cooper, 1997) . Indeed, this lectin promotes adhesion of normal and cancer cells to laminin (Ellerhorst et al, 1999; Mahanthappa et al, 1994; van den Brûle et al, 1995; Zhou and Cummings, 1990) as well as to other biologic components (Ahmed et al, 1992; Stojanovic et al, 1983) . These biologic phenomena are probably related to the homodimeric structure of gal-1. Proliferation of normal and malignant cells is modulated by gal-1: growth inhibition is observed at high gal-1 concentrations, whereas lower concentrations of gal-1 induce a stimulation of cell proliferation (Adams et al, 1996) . Other functions of gal-1 have also been highlighted, such as participation in the process of pre-mRNA splicing (Vyakarnam et al, 1997) . Gal-1 also induces apoptosis of activated T cells, through binding to cell surface CD45 (Perillo et al, 1995) and CD7 molecules (Pace et al, 2000) , a property that could protect the cancer cells against T-cell immune response.
Expression of gal-1 in malignant tumors has been examined in various cancer types. Increased gal-1 expression has been demonstrated in human cancers, including those arising from thyroid (Chiariotti et al, 1992 (Chiariotti et al, , 1995 Xu et al, 1995) , endometrium (van den Brûle et al, 1996) , head and neck (Gillenwater et al, 1996) , thymus (Hafer-Macko et al, 1996) , bladder (Cindolo et al, 1999) , pancreas (Berberat et al, 2001) , and colon (Sanjuan et al, 1997 ) and those such as cholangiocarcinoma (Shimonishi et al, 2001 ) and glioma (Rorive et al, 2001 ). Gal-1 was also described in the stroma associated with cancer cells (Gillenwater et al, 1996; Sanjuan et al, 1997) . We recently demonstrated that preferential accumulation of gal-1 in the stroma associated with prostate carcinoma cells is related to progression of the disease (van den Brûle et al, 2001) .
In this study, we examined gal-1 expression in a collection of human ovary carcinoma samples, and we observed significantly increased expression of gal-1 in the stroma adjacent to carcinoma cells, compared with noninfiltrated stroma. We then conducted in vitro experiments to better understand this phenomenon and its influence on the behavior of ovary carcinoma cells.
Results

Expression of Galectin-1 in Human Ovary Carcinoma Samples
We first examined gal-1 expression in 30 human ovary carcinoma samples by Northern and Western blotting and by immunohistochemistry. The gal-1 mRNA message was detected in all of the ovary carcinomas RNA samples on Northern blots. Analysis of the Northern blotting data demonstrated that more than 95% (25 of 26) of the samples showed increased glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-normalized gal-1 mRNA levels when compared with an RNA sample extracted from a wedge resection from a normal ovary. Western blotting experiments using the anti-gal-1 antibody showed a single 14-kDa band in all of the ovary carcinomas samples (Fig. 1 , A to C), as expected (van den Brûle et al, 1996) . The results of gal-1 detection from the Northern and Western blotting and from immunohistochemistry experiments (Fig. 1 , A to C) showed the best correlations in the more cellular tumors, mainly because of the heterogeneity in some of the examined tissues and the fact that gal-1 is also found in normal cells and in the stroma.
Figure 1.
Expression of galectin-1 (gal-1) in human ovary carcinoma samples and colocalization with laminin-1 and fibronectin. A to C, Typical examples of gal-1 expression in human ovary carcinomas, as determined by Northern blotting using the gal-1 (a) and glyceraldehyde-3-phosphate dehydrogenase (b) cDNA probes, by Western blotting (c), and by immunohistochemistry (right part of the panels A to C, and panels D and E). Serous carcinomas expressing low and high levels of gal-1 are respectively shown in A and B; C shows a mucinous carcinoma. D, gal-1 positivity is found in invading carcinoma cells and in the adjacent stroma. E, An example of strong positivity of the stroma infiltrated by the carcinoma cells (left part of the panel), compared with the stroma that is not invaded (right part of the panel). F, (In situ hybridization) strong, predominant mRNA expression of gal-1 in stroma cells and moderate expression into the carcinoma cells. The last three panels show an example of colocalization of gal-1 (G), laminin-1 (H), and fibronectin (I). Original magnification: ϫ630 (A to C), ϫ400 (D and F), and ϫ100 (E and G to I).
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Because of its cell type specificity, immunohistochemistry was considered as the most reliable detection technique, allowing discrimination between normal and neoplastic tissue. Gal-1 expression was heterogeneous from sample to sample. Cancer cells and stroma were often positive. Tumor epithelial cells were clearly positive in 17 of the 30 cases, with a cytoplasmic pattern. Statistical analysis of the data revealed that gal-1 expression was significantly higher in mucinous carcinomas compared with serous tumors (2.33 Ϯ 0.58, n ϭ 3, vs 0.66 Ϯ 0.77, n ϭ 19, p ϭ 0.027, Wilcoxon-Mann-Whitney test; Fig. 1) .
In some samples, gal-1 could be detected in both invading carcinoma cells and their surrounding stroma (Fig. 1, E) , suggesting release of the lectin. Examination of the stroma associated with the carcinoma cells demonstrated that it was positive for gal-1 immunostaining in a large majority of samples (score 1 in 20 of 24 cases). However, the stroma associated with the normal tissue, when present on the slide, was characterized by low or absent immunostaining (score 0 in 9 of 9 cases). Statistical analysis demonstrated a significant increase of gal-1 expression in the stroma adjacent to carcinoma cells compared with the stroma that was not infiltrated by the carcinoma cells (0.83 Ϯ 0.38, n ϭ 24, vs 0 Ϯ 0, n ϭ 9, p ϭ 0.003, WilcoxonMann-Whitney test; Fig. 1E ). To verify gal-1 mRNA expression by the different cell types, we also conducted in situ hybridization on 12 other frozen epithelial ovary carcinoma samples (Fig. 1F) . Expression of gal-1 mRNA was predominantly found in stromal cells close to carcinoma cells, in all samples; moderate staining was also observed in carcinoma cells. No other correlation between gal-1 expression (determined by immunohistochemistry) and available clinicopathologic features of the ovary carcinomas samples could be established.
Colocalization of Galectin-1, Laminin-1, and Fibronectin in Ovary Carcinoma
We also examined the presence of laminin-1 and fibronectin in carcinoma cell-associated stroma in 35 ovary carcinoma samples by immunohistochemistry, because it is known that cancer cells express and secrete these molecules (Christensen, 1992; Hunt, 1989) . The majority of the cases showed conspicuous colocalization of gal-1, laminin-1, and fibronectin (Fig.  1, G to I ). Twenty cases (57.1%) presented with conspicuous accumulation of gal-1 in the cancerassociated stroma, whereas 21 and 15 showed positivity for laminin-1 and fibronectin, respectively. Of the 20 cases that were positive for gal-1 in the cancer cell-associated stroma, 16 (80%) and 12 (60%) were also positive for laminin-1 and fibronectin, respectively. Statistical analysis of these data revealed correlation coefficients of 0.471 and 0.400 between stromal gal-1 and either laminin-1 or fibronectin (p ϭ 0.0038 and 0.0166, respectively).
Expression of Galectin-1 in Human Ovary Carcinoma Cell Lines
We first examined gal-1 expression in six human ovary carcinoma cell lines by Western blotting (Fig. 2 , upper left panel). Gal-1 was detected in the AZ364, SK-OV-3, and AZ224 but not in the OVCAR-3, AZ419 and AZ382 cell extracts. Because gal-1 exerts interactions with extracellular matrix components, we examined cell surface expression of gal-1 in the cell lines by flow (Fig. 2) . No results could be obtained for the AZ382 cell line, because it formed cell clumps that could not be resolved to single-cell suspension. A shift of fluorescence intensity was observed with the three cell lines that were positive for gal-1 expression by Western blotting, ie, AZ364, SK-OV-3, and AZ224; the three other cell lines were negative. Because we observed gal-1 in the stroma surrounding ovary carcinoma cells in the pathologic specimens, we concentrated (ϫ70) the conditioned media (CM) using Centricon devices and observed the presence of gal-1 in those/the CM harvested from the three gal-1-positive cell lines. However, crude, nonconcentrated CM as well as the pass-through filtrate fractions from the Centricon procedure did not show the presence of gal-1 by Western blotting (not shown).
Effect of Ovary Carcinoma-Derived CM on Galectin-1 Expression in Human Fibroblasts
Because we observed that fibroblasts surrounding cancer cells were positive for gal-1 immunostaining, we tested the possibility that host fibroblasts could constitute a source of gal-1 in the cancer cell-associated stroma. Western blotting analysis demonstrated that cell extracts from in vivo-grown 84BR fibroblasts show gal-1 expression; we also observed the presence of the lectin in the ϫ70 concentrated 84BR CM (Fig. 3A) , consistent with gal-1 release from the fibroblasts.
To determine whether the ovary carcinoma cells could modulate gal-1 protein expression in the surrounding fibroblasts of the stroma, we treated human 84BR fibroblasts for 48 hours with various ovary carcinoma cell CM. Gal-1 expression was determined by Western blotting and quantified (Fig. 3B ). Incubation with OVCAR-3, AZ224, AZ364, and AZ382 CM reproducibly increased gal-1 protein expression in the 84BR fibroblasts. No modulation was observed when the 84BR fibroblasts were treated with AZ419 and SK-OV-3 CM. The observed modulations cannot be explained by the presence of gal-1 in the CM, because OVCAR-3-and AZ382-concentrated CM are characterized by the absence of gal-1 (Fig. 2) .
Modulation of Human Ovary Carcinoma Cell Incorporation of Bromodeoxyuridine (BrdU) by Galectin-1
It has already been demonstrated in other models that gal-1 modulates cell growth (Adams et al, 1996) . We thus tested the effect of recombinant gal-1 on the proliferation of ovary carcinoma cell lines using a BrdU incorporation assay. Two experimental protocols were used. In the first one, cells were seeded in plates and immediately incubated with gal-1 for 48 hours. In the second protocol, the cells were cultured in complete medium for 1 day and then incubated with gal-1 for 48 hours as above. Similar results were obtained with these two types of experiments and were averaged to generate Figure 4 . Low concentrations of recombinant gal-1 did not significantly affect BrdU incorporation; higher concentrations (100 g/ml) induced a significant decrease in BrdU incorporation in all six ovary carcinoma cell lines (Fig. 4) .
Modulation of Human Ovary Carcinoma Cell Attachment to Laminin-1 and Fibronectin by Galectin-1
Because our data demonstrate the presence of gal-1 in the stroma surrounding the ovary carcinoma cells, we examined the effect of recombinant gal-1 on the ability of ovary carcinoma cell lines to adhere onto laminin-1 and fibroblast fibronectin. The adhesion profiles of the examined cell lines were first determined (Fig. 5A) . The free-floating cells (AZ419 and AZ382) did not show significant adhesion to laminin-1 or fibronectin; adhesion to laminin-1 reached 30% (AZ364) and adhesion to fibronectin reached 100% (OVCAR-3) after 120 minutes. Then, the effect of recombinant gal-1 on cell adhesion was evaluated. Addition of increasing concentrations of gal-1 (0 to 400 g/ml; Fig. 5B ) induced a dose-dependent increase in adhesion to laminin-1 in AZ224 and AZ382 cells, and to a lesser extent in SK-OV-3 cells (maximum fold increase in attachment value after a 30-minute incubation period, 2.87, 6.19, and 1.81, respectively). No significant effect was observed in OVCAR-3, AZ364, and A419 cells. Adhesion to fibronectin after 30-minute incubation was increased by Expression, release, and modulation of gal-1 expression in 84BR fibroblasts by ovary carcinoma CM. Gal-1 was detected by Western blotting in cell extracts (CE) and ϫ70 concentrated conditioned medium (CMC) but not in crude conditioned medium or the pass-through filtrate from the concentration procedure (CMU) (A). After incubation of the fibroblasts for 48 hours with ovary carcinoma cell-conditioned medium, fibroblast extracts were analyzed by Western blotting and the blots were analyzed by densitometric analysis as described in "Material and Methods." The values obtained in the examined conditions were divided by the control value (ie, incubated with nonconditioned medium; C). Values used in the bar graph (B) correspond to the mean Ϯ SD of three independent experiments. van den Brûle et al addition of gal-1 in OVCAR-3 cells (5.4-fold); moderate increases were observed in AZ224 and SK-OV-3 cells (1.5-and 1.7-fold, respectively). No modulation of adhesion was observed in AZ364, AZ382, and AZ419 cells.
Discussion
Our study demonstrates that gal-1 expression is increased in human ovary carcinoma tissues. This observation is in agreement with previous reports of gal-1 overexpression in other malignant lesions (Berberat et al, 2001; Chiariotti et al, 1992 Chiariotti et al, , 1995 Cindolo et al, 1999; Gillenwater et al, 1996; Hafer-Macko et al, 1996; Rorive et al, 2001; Sanjuan et al, 1997; Shimonishi et al, 2001; van den Brûle et al, 1996; Xu et al, 1995) . Recently, another example of gal-1 mRNA overexpression was provided in a androgenindependent LNCaP variant compared with the parental, androgen-dependent cell line (Vaarala et al, 2000) .
In ovary carcinoma, gal-1 preferentially accumulates in the adjacent peritumoral stroma. Although such an accumulation has also been reported in the stroma surrounding thyroid (Xu et al, 1995) , head and neck (Gillenwater et al, 1996) , colon (Sanjuan et al, 1997) , and prostate carcinoma (van den Brûle et al, 2001) , the mechanisms responsible for this phenomenon and its consequences on tumor progression have not been investigated. We therefore conducted experiments to elucidate the mechanisms that lead to gal-1 accumulation in the stroma adjoining ovary cancer cells. Using in situ hybridization experiments, we clearly demonstrated that fibroblast cells, adjacent to the malignant cells, express gal-1 mRNA and contribute, at least in part, to gal-1 accumulation. Ovary carcinoma cells likely intervene also in this process because we observed that they express gal-1 mRNA Gal-1 modulates ovary carcinoma cell proliferation. Cell proliferation was assessed using a bromodeoxyuridine incorporation assay, in the presence of increasing amounts of recombinant gal-1 (x axis; g/ml). The results are expressed as percentage of the control value (ie, without addition of gal-1). *p Ͻ 0.05 (Student's t test). See "Materials and Methods" for details. and release the corresponding protein into the medium.
Ovary Carcinoma and
The observation that fibroblasts immediately adjacent to the ovary cancer cells were more positive for gal-1 at both the mRNA and protein levels compared with distant fibroblasts suggested that the malignant cells might be responsible for their gal-1 expression. Such a hypothesis was supported by the demonstration that conditioned medium obtained from ovary carcinoma cells induced an increased gal-1 expression in 84BR fibroblasts.
We then demonstrated that gal-1 accumulated in the cancer-associated stroma can decrease cell proliferation and modulate cell adhesion to laminin-1. The first event could be viewed as a defense mechanism from the host against the tumor, because stromal gal-1 could contribute to decreased cancer cell proliferation in vivo.
Although the decreased cell proliferation induced by gal-1 was observed in all six tested cell lines, promotion of cell adhesion to laminin-1 or fibronectin by gal-1 was found in three of the six cell lines. Cell line selectivity was neither related to gal-1 expression in the cell lines nor to their ability to attach to plastic. Gal-1, as a homodimeric molecule (Bourne et al, 1994; Liao et al, 1994) , is likely to bridge immobilized laminin-1 to glycoconjugates located on the cell surface, such as laminins and/or Lamps. The known expression of those molecules in cancer cells and their ability to bind galectins (van den Brûle and Castronovo, 2000) could be the reason for this specificity of cell behavior. Our observations suggest that gal-1 accumulated at the border between the cancer cells and the host stroma could modulate these interactions and hence promote invasion. Stromal gal-1 could also decrease proliferation of the fibroblasts in an autoand paracrine fashion (Adams et al, 1996) and, as a consequence, impair the host reaction to circumvent the tumor by creating a fibrous capsule to restrain its progression.
Another putative role for gal-1 accumulated around the tumor could be the modulation of the local antitumor immune response. Indeed, gal-1 modulates TCR signals (Vespa et al, 1999 ) and cytokine production (Rabinovich et al, 1999) and induces apoptosis of activated T lymphocytes through binding to the polylactosamine-enriched CD45RO (Perillo et al, 1995) and CD7 (Pace et al, 1999) . Gal-1 could therefore constitute an immunologic shield that protects cancer cells against host immune response.
The global effect of these biologic events for tumor progression is likely to result from a balance between "negative" events, such as decreased ovary cancer cell proliferation, and apparently favorable effects for tumor progression, including promotion of cancer cell adhesion and defense against host immune response. The relative importance of all these elements, and the positive or negative global effect for tumor progression, could be different depending on the tumor type. We already demonstrated a positive correlation between preferential accumulation of gal-1 in cancerassociated stroma and progression of prostate cancer (van den Brûle et al, 2001 ). Thus, more detailed evaluation of the prognostic significance of this parameter in other human cancers as well as of the role of gal-1 in cancer progression is mandatory.
In conclusion, our findings demonstrate increased expression of gal-1 in human ovary carcinoma cells and preferential accumulation in cancer-associated stroma, a finding that could be important for cancer progression. These data support a role for gal-1 in the crosstalk between cancer cells and the associated stroma and in modulation of the biologic behavior of the cancer cells. The influence of host-derived versus cancer cell-derived gal-1 on cancer progression remains to be further elucidated.
Materials and Methods
Ovary Carcinoma Tissue Samples
Two groups of ovary carcinoma samples were examined. The first was used for Northern and Western blotting experiments and for immunohistochemistry. Thirty-five samples of human ovarian carcinoma samples were obtained from the Department of Gynecological Oncology (Duke University Medical Center, Durham, North Carolina) (van den Brûle et al, 1994) . Thirty samples were examined for gal-1 expression by immunohistochemistry. Twenty-six samples were from primary tumors and four from recurrences (obtained after primary treatment including chemotherapy). For each sample, clinicopathologic data with histologic type and grade were available. In the group, there were 20 serous and 3 mucinous tumors (other types: n ϭ 7); the majority (n ϭ 17) of the tumors were moderately differentiated, and 9 were poorly differentiated. Surgical staging was established according to the FIGO staging system (International Federation of Gynecology and Obstetrics, 1987) . There were 2 Stage I, 4 Stage II, 18 Stage III, and 6 Stage IV carcinomas. Colocalization of gal-1, laminin-1, and fibronectin was examined by immunohistochemistry in slides from the 35 paraffin blocs.
The second group, consisting of 12 liquid nitrogen frozen, TEK-embedded epithelial ovary carcinoma samples, was obtained from the Tumors and Tissue Bank of the Department of Anatomic Pathology, Hospital Clinic Provincial, Barcelona.
Northern and Western Blotting
Total cellular RNA was extracted from the powdered frozen tissue samples. Of the 30 samples, 23 were sufficient to allow RNA extraction by guanidine isothiocyanate lysis-cesium chloride cushion centrifugation (Glisin et al, 1974) . Northern blotting was performed according to standard procedures using gal-1 (van den Brûle et al, 1995) and GAPDH (Ercolani et al, 1988; Piechaczyk et al, 1984) probes. X-ray films were exposed and quantified using the public domain NIH Image 1.62 software program for the Apple Macintosh (developed at the United States National Institutes of Health and available at http://rsb.info.nih.gov/nih-imvan den Brûle et al age/). The normalized gal-1/GAPDH ratios were used as values for subsequent analyses.
Total protein extracts were performed in 1% SDS from the 24 largest powdered tissue samples. Fifteen micrograms of protein extract, as determined by a bicinchoninic acid protein assay (MicroBCA; Pierce Chemical Company, Rockford, Illinois), were separated by size on 15% SDS-polyacrylamide gels, transferred to a polyvinylidene difluoride membrane (PVDF; Immobilon, Millipore Corporation, Brussels, Belgium). Western blotting was performed using an affinitypurified rabbit polyclonal anti-recombinant gal-1 antibody (a gift from D. N. W. Cooper, University of California at San Francisco, California) (Cooper and Barondes, 1990 ) and a chemoluminescence reaction procedure (Roche, Brussels, Belgium). If needed, signal quantification was performed using NIH Image, as described above.
Immunohistochemistry
Immunoperoxidase staining of gal-1 was performed in paraffin sections of 27 formalin-fixed samples of ovary carcinoma with the above-described anti-gal-1 antiserum (Cooper and Barondes, 1990) , which was extensively characterized for specificity (van den Brûle et al, 1996 (van den Brûle et al, , 2001 ). The avidin-biotin peroxidase complex method was used as previously described (Hsu et al, 1981; van den Brûle et al, 1996) (ABC Vectastain Elite Kit; Vector Laboratories, Burlingame, California). Briefly, sections were deparaffinized in xylene and rehydrated in PBS (10 mM sodium phosphate, 0.9% NaCl, pH 7.5). Blocking of the endogenous peroxidase was performed with 0.3% H 2 O 2 in methanol, and the nonspecific serum-binding sites were saturated with normal goat serum. The slides were incubated for 2 hours at room temperature with the diluted anti-gal-1 antiserum, for 30 minutes with the secondary biotinylated antibody, and then with the biotinylated horseradish peroxidase complex. Peroxidase activity was revealed by the 3,3'-diaminobenzidine tetrahydrochloride reaction (Graham and Karnovsky, 1966) , and sections were finally counterstained with hematoxylin. Staining of the slides was evaluated by three independent observers in a blinded fashion, using an arbitrary semiquantitative scale: 0, negative; 1, focal areas with sparse staining or occasional individual positive cells; 2, at least one focus with extensive staining or numerous areas with weak to moderate staining; and 3, extensive staining of more than 50% of the neoplastic cells. Immunostaining was also examined in the stroma infiltrated by the carcinoma cells and in the noninfiltrated stroma; it was evaluated by an arbitrary scale as follows: 0, absence of staining or positivity in Ͻ50% of the evaluable stroma; and 1, positivity in more than 50% of the evaluated stroma. The evaluations of gal-1 immunostaining by the three observers were alike, and their mean was used in the statistical tests. The differences between the values of various groups of ovarian carcinoma specimens were determined by the nonparametric double-sided WilcoxonMann-Whitney test, using the Statview statistics software package for the Macintosh (SAS Institute Inc., Cary, North Carolina). The specificity of the antibody was assessed by omission of the first antibody (not shown). Immunostaining of 35 ovary carcinoma samples from the first examined group was also performed using rabbit anti-laminin-1 and guinea pig antifibronectin polyclonal antisera, kindly provided by Professor J.-M. Foidart (University of Liège, Belgium). Evaluation of the positivity of the stroma located around the carcinoma cells was performed as described above. Correlation coefficients were calculated using Statview.
In Situ Hybridization
The presence of gal-1 mRNA transcripts in primary ovary cancer samples was demonstrated by a nonradioactive in situ hybridization technique, as previously described (van den Brûle et al, 1999) . The antisense and sense riboprobes were synthesized using a DIG RNA labeling kit and T7 polymerase (Roche) from the F14-3AS and F14-4S plasmids as previously described (van den Brûle et al, 1999) . Specificity controls included observation of the absence of staining using sense probes in each case. In addition, AZ224 and OVCAR-3 epithelial ovary carcinoma cells were used as positive and negative controls, respectively, as previously described (van den Brûle et al, 1999) .
Cell Lines, Tissue Culture, and CM
Human Caov-3, SK-OV-3, and OVCAR-3 epithelial ovary cancer cell lines were obtained from the American Type Culture Collection (Rockville, Maryland) and routinely grown in DMEM supplemented with 10% fetal bovine serum (FBS) (Caov-3), McCoy's 5a supplemented with 15% FBS (SK-OV-3), or RPMI 1640 with 10 g/ml insulin and 10% FBS (OVCAR-3). The AZ224, AZ364, AZ382, and AZ419 ovary carcinoma cell lines were obtained from Dr. Jacques de Grève (Academisch Ziekenhuis, Vlaamse Universiteit Brussel, Brussels, Belgium). The two latter cell lines grow as free-floating cells, and the others are adherent cell lines. The AZ224 cell line was grown in RPMI 1640 supplemented with 20% FBS and 100 IU/ml glutamine; the AZ364, AZ382, and AZ419 cell lines were grown in RPMI 1640 supplemented with 10% FBS and 250 nM dexamethasone. CM were collected as follows. After extensive rinses with PBS, preconfluent ovary carcinoma cells were incubated for 48 hours in FBS-free DMEM. The CM was collected and centrifuged to remove cell debris and stored at Ϫ80°C until use. Concentration was performed using Centricon YM-10 centrifugal filter devices (molecular weight cut off, 10,000 D; Amicon, Millipore, Brussels, Belgium). The CM were checked for pH and glucose and lactate concentrations before treatment of the 84BR fibroblasts to examine gal-1 modulation of expression and to verify that the pH values were in the 7.2 to 7.4 range, that glucose concentrations varied between 3.0 and 3.8 g/L, and that the lactate concentrations were below 600 mg/L. The 84BR fibroblast cell line was obtained from the European Tissue Culture Collection (ECACC, Salisbury, United Kingdom) and was grown in MEM supplemented with 15% FBS and 1% nonessential amino acids. Antibiotics (100 g/ml penicillin, 100 g/ml streptomycin) were added to all culture media. The cell lines were grown in a humidified atmosphere of 5% CO 2 /95% air at 37°C. All tissue culture reagents were obtained from Life Technologies (Merelbeke, Belgium). CM were harvested and concentrated as described above.
Flow Cytometry
Ovary carcinoma cell lines were analyzed for expression of gal-1 at the cell surface by flow cytometry. Briefly, ovary carcinoma cells were harvested using 2 mM EDTA in calcium-magnesium-free PBS. One million cells were suspended at 5 ϫ 10 6 cells/ml in HBSS (GibcoBRL, Life Technologies) in a total volume of 200 l and incubated with diluted anti-gal-1 polyclonal antibody (1/5000) (Cooper and Barondes, 1990) for 30 minutes at 4°C (thick lines, Fig. 2 ). Control cells were incubated similarly but without primary antibody (thin lines, Fig. 2 ). The cells were washed twice in HBSS and incubated with an anti-rabbit IgG FITCconjugated secondary antibody (dilution 1/160; Sigma, Bornem, Belgium) for 30 minutes at 4°C. After two washes, cell surface fluorescence was analyzed using a FACSCalibur cytometry unit (Becton Dickinson, Erembodegem, Belgium). A scatter window was set to eliminate dead cells and cell debris, and the results were presented as histograms.
Treatment of Human Fibroblasts with CM from Ovary Carcinoma Cells
To explore the possible interactions between the ovary carcinoma cells and the fibroblasts, we tested the influence of CM collected from ovary carcinoma cell lines on the two types of fibroblasts. Preconfluent fibroblasts were incubated with ovary carcinoma CM for 48 hours. After this time, protein extracts were performed using 1% SDS and processed for Western blotting using the anti-gal-1 antibody as described above. The values obtained in the examined conditions were divided by the control value (ie, fibroblasts incubated with nonconditioned medium). Three independent experiments were conducted, and the means and SD were calculated.
Cell Proliferation Assay
The effect of IA-treated recombinant gal-1 on ovary carcinoma cell proliferation was assessed as follows. Ten thousand ovary carcinoma cells were seeded in each well of 96-well plates; the cells were allowed to attach and were incubated overnight at 37°C in 200 l of their usual culture medium. After overnight incubation, the culture medium was removed, the cells were thoroughly washed with PBS, and recombinant gal-1 diluted at specified concentrations in 200 l DMEM was added to the cells. Cell proliferation was measured after 48-hour treatment, using a colorimetric assay based on the measurement of BrdU incorporation during DNA synthesis, according to the manufacturer's protocol (Roche). In another set of experiments, 6000 cells were seeded in each well in complete growth medium, allowed to attach, and cultured 1 day in DMEM before adding recombinant gal-1 diluted in DMEM containing 2% FBS. The statistical significance of the results was determined using the Student's t test.
Attachment of Ovary Carcinoma Cells to Laminin and Fibronectin
Attachment assays were performed as described (van den Brûle et al, 1995) . Briefly, Immulon I Removawell strips (Dynatech Labs, Chantilly, Virginia) were coated overnight at 37°C with 10 g purified EngelbrethHolm-Swarm laminin-1 or human fibroblast fibronectin (Calbiochem-Merck, Leuven, Belgium), washed with PBS, and blocked for 1 hour with 1% BSA. After trypsinization and a 2-hour recovery period, 50,000 cells labeled overnight with [
35 S]methionine (Tran 35 SLabel; ICN, Irvine, California) and resuspended in serum-free medium containing 0.1% BSA were added to the wells. The cells were incubated in a 5% CO 2 / 95% air incubator at 37°C for specified periods of time. The assay was stopped by aspiration of the media and three gentle washes with PBS; attached cells were lysed in 1% SDS, and the percentage of attached cells was determined by scintillation counting and comparison to the radioactivity of 50,000 labeled cells. In other experiments, recombinant gal-1 was added to the cells at specified concentrations, and the attachment values were evaluated after 30-minute incubation. Recombinant gal-1 was purified by lactose affinity chromatography and alkylated using iodoacetamide to prevent oxidation as previously described (Cooper et al, 1991) . The attachment values obtained were divided by the corresponding control values, ie, without addition of gal-1. All experiments were conducted in quadruplicates and were reproduced at least three times.
